Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
34.00
+1.55 (+4.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
523,756
Open
32.62
Bid (Size)
31.75 (4)
Ask (Size)
46.66 (1)
Prev. Close
32.45
Today's Range
32.08 - 35.07
52wk Range
13.36 - 41.31
Shares Outstanding
27,433,359
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
August 14, 2024
Via
Benzinga
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Via
Investor's Business Daily
Performance
YTD
+56.68%
+56.68%
1 Month
+0.89%
+0.89%
3 Month
+35.95%
+35.95%
6 Month
+42.68%
+42.68%
1 Year
+69.41%
+69.41%
More News
Read More
S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday
August 14, 2024
Via
Benzinga
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 14, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
4 Analysts Assess AnaptysBio: What You Need To Know
August 06, 2024
Via
Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
August 05, 2024
Via
InvestorPlace
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On AnaptysBio
May 10, 2024
Via
Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Unveiling 4 Analyst Insights On AnaptysBio
April 01, 2024
Via
Benzinga
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Via
InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
April 12, 2024
Via
The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
March 12, 2024
Via
Benzinga
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
February 29, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
January 31, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
November 07, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.